When was Margetuximab/Meganex launched on the market?

Margetuximab is an important innovative drug in the field of HER2-targeted therapy and has received marketing approval both internationally and domestically. In the United States, the drug was approved by the FDA on December 16, 2020, under the trade name MARGENZA, for the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received Herceptin treatment. After its launch, margetuximab quickly entered multiple clinical guidelines and became an important option for the precision treatment of advanced breast cancer.

In China, the original drug margituximab was approved for marketing by the State Food and Drug Administration on August 29, 2023. The brand name is Magituximab. This approval marks the first time that domestic patients can obtain this innovative drug through local channels without relying on overseas purchasing or clinical trial channels. After the drug is launched, it provides patients with more treatment options for HER2-positive breast cancer, and also promotes the development of domestic precision medicine and immunotherapy.

Currently, there are no generics or biosimilars of margetuximab in the global market, and all supplies are original drugs. This ensures the consistency of drug quality and efficacy to a certain extent, but it also means that the price is still relatively high, and clinical use requires reasonable planning based on the patient's condition, economic conditions, and the doctor's treatment plan. Since the drug is mainly used for advanced patients whose disease has progressed after previous Herceptin treatment, its use has clear clinical indications.

In addition to time to market, clinicians and patients also need to pay attention to medication regimens, delivery methods, and monitoring indicators. Margetuximab is usually administered by intravenous infusion and requires regular follow-up to assess efficacy and tolerability. At the same time, the adverse reactions of the drug are relatively controllable, mainly including infusion-related reactions and some immune-related reactions, and patients can manage them under the guidance of professional medical care.

Reference materials:https://www.margenza.com/